Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.86%
0%
-8.86%
6 Months
122.3%
0%
122.3%
1 Year
58.71%
0%
58.71%
2 Years
82.29%
0%
82.29%
3 Years
-24.59%
0%
-24.59%
4 Years
-51.67%
0%
-51.67%
5 Years
-67.28%
0%
-67.28%
Théraclion SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-13.93%
EBIT Growth (5y)
-8.44%
EBIT to Interest (avg)
-5.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.33
Tax Ratio
18.73%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
30.03
EV to EBIT
-4.35
EV to EBITDA
-4.40
EV to Capital Employed
-9.48
EV to Sales
27.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-873.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'21
Change(%)
Net Sales
1.80
1.50
20.00%
Operating Profit (PBDIT) excl Other Income
-3.20
-4.70
31.91%
Interest
2.00
0.10
1,900.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.70
-3.80
2.63%
Operating Profit Margin (Excl OI)
-1,732.20%
-3,198.50%
146.63%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 20.00% vs 114.29% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 2.63% vs 2.56% in Dec 2021
About Théraclion SA 
Théraclion SA
Pharmaceuticals & Biotechnology
Theraclion is a France-based company, which develops High Intensity Focused Ultrasound (HiFu) machines. The Company is a a spin-off of Inserm and EDAPTechomed. The main activity of the Company is developping, manufacturing and marketing echotherapy medical equipments associating therapy by focused ultrasound and monitoring by ultrasound. The Company provides Echopulse, a device for the non-invasive and outpatient treatment of the fibroadenoma of the breast and thyroid nodules.
Company Coordinates 
Company Details
102, rue Etienne Dolet , MALAKOFF None : 92240
Registrar Details






